The CDC expanded RSV vaccine recommendations to include adults aged 50 and above who have underlying health conditions ...

The latest announcement is out from Merck & Company ( (MRK) ).

Merck MRK stock has declined 4% since it announced second-quarter results on July 29 before market open. While the company’s ...

The Nobel Prize-winning technology underpinning COVID-19 vaccines is also fueling a host of biotechs developing treatments ...

Merck (MRK) may be a storied pharmaceutical giant with a 134-year history, but it still has a lot of room to run. Merck is well-known for its cancer treatment Keytruda, vaccine leadership, and a ...

A new study shows that while RSV mostly affects younger kids, the often-overlooked human metapneumovirus also hospitalizes ...

Engine Capital urges Avantor board changes; China's Ab&B Bio-Tech shares soar; French chlorine factory fire prompts alert; IO ...

The system for compensating people injured by vaccines needs significant reform. But the health secretary could alter it in ...

Merck & Co., Inc. (NYSE:MRK) is one of the best dividend stocks in the pharma sector. The company has a strong lineup of products in development and brings in solid revenue and earnings. It ...

Health and Human Services Secretary Robert F. Kennedy Jr. misrepresented the country’s compensation program for those who are ...

Reports second quarter revenues of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.13) Updates 2025 ...